The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 17 of the 23 sources its claims cite were checked for support.
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study
Open accessAbstract
Background Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder in which the use of immunotherapy and the long-term outcome have not been defined. Methods In this multi-institutional observational study (2007-2012), all patients with GluN1 antibodies were assessed at symptom onset and 4, 8, 12, 18, and 24 months using the modified Rankin Scale (mRS). Treatment included first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line immunotherapy (rituximab, cyclophosphamide), and tumor removal. Predictors of outcome were determined at the Universities of Pennsylvania and Barcelona using generalized linear mixed models with binary distribution. Results 577 patients (1-85 years, median 21) were studied, 212 were children (<18 years). Treatment effects and outcome were assessable in 501 (median follow-up 24 months): 472 (94%) underwent first-line immunotherapy or tumor removal, resulting in improvement within four weeks in 251 (53%). Of 221 patients who failed first-line therapy, 125 (57%) received second-line immunotherapy resulting in better outcome than those who did not (OR 2·69, CI 1·24-5·80, p=0·012). During the first 24 months, 394/501 reached good outcome (mRS 0-2; median 6 months), and 30 died. At 24 month follow-up 204/252 (81%) had good outcome. Outcomes continued to improve for up to 18 months after symptom onset. Predictors of good outcome were early treatment (OR 0·62, CI 0·50-0·76, p<0·0001) and lack of ICU admission (OR 0.12, CI 0·06-0·22,p<0·0001). 45 patients had one or multiple relapses (representing a 12% risk within 2 years); 46/69 (67%) relapses were milder than previous episodes (p<0·0001). In 177 children, predictors of good outcome and the magnitude of effect of second-line immunotherapy were comparable to those of the entire cohort. Conclusions Patients with anti-NMDAR encephalitis respond to immunotherapy. Second-line immunotherapy is usually effective when first-line therapies fail. Recovery can take more than 18 months.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In this multi-institutional observational cohort of 577 patients with anti-NMDAR encephalitis, immunotherapy and tumor removal produced good outcome (mRS 0–2) in 394/501 within 24 months, and second-line immunotherapy improved outcomes after first-line failure. Early treatment and no ICU admission predicted good outcome.
Key findings
- 577 patients (1–85 years, median 21) were studied; 211 (37%) were younger than 18 in the Results (the abstract states 212 children). Of 501 assessable patients, 472 (94%) received first-line immunotherapy or tumor removal, and 251 (53%) improved within four weeks.
- Of 221 patients who failed first-line therapy, 125 (57%) received second-line immunotherapy, which was associated with better outcome than no second-line therapy (OR 2·69, CI 1·24–5·80, p=0·012).
- During the first 24 months, 394/501 reached mRS 0–2 (median 6 months); at 24-month follow-up 203/252 (81%) had good outcome, and 24 (9·5%) died in the Results (the abstract reports 30 died). Predictors of good outcome were early treatment (OR 0·62, CI 0·50–0·76, p<0·0001) and lack of ICU admission (OR 0·12, CI 0·06–0·22, p<0·0001).
- 45 patients had relapses, representing a 12% risk within 2 years; 46/69 (67%) relapses were milder than previous episodes (p<0·0001). In 177 children, predictors of good outcome and the magnitude of second-line immunotherapy effect were comparable to the entire cohort (OR 3·35, CI 0·86–12·98, p=0·081).
Methods
- Multi-institutional observational study (2007–2012) of patients with GluN1 antibodies from the Universities of Pennsylvania and Barcelona and samples from 200 centers worldwide (32 countries); 577 patients were included for demographic analyses, and 501 had follow-up of at least 4 months (median 24 months, range 4–186).
- Patients were assessed at symptom onset and 4, 8, 12, 18, and 24 months using the modified Rankin Scale (mRS); symptoms were categorized into 8 groups. First-line immunotherapy was steroids, IVIg, or plasma exchange; second-line was rituximab or cyclophosphamide; tumor removal was also assessed. Treatment failure was no sustained improvement within four weeks and mRS ≥4.
- Statistical analysis used Fisher exact, Fisher-Freeman-Halton, or Mann-Whitney U tests; univariable binary logistic regression followed by generalized linear mixed models with binary distribution, subject as random effect, and time point from disease onset included; SAS GLIMMIX version 9.3.
Limitations
- The paper states the study was not randomized, was observational, and selection bias cannot be ruled out; individual treatments (e.g., plasma exchange vs IVIg or rituximab) could not be compared side-by-side statistically.
- The paper states there was no predefined protocol establishing order or combination of treatments, and treatment decisions were made by treating physicians based on clinical symptoms, family acceptance of side effects, and drug availability.
- The paper states that ending follow-up at 24 months likely underestimates recovery and overestimates mortality; imputation analysis estimated 7% mortality at 24 months. The text also shows inconsistent counts between abstract and Results for deaths, children, and 24-month good outcome, which is evident from the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
66 Own result · 11 Own interpretation · 10 Partly supported · 9 Own method · 2 Supported · 2 Sources not found · 2 No basis given · 1 Supported so far · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The lower frequency of neurological relapses (12% versus 20-24% reported in previous studies)11, 18 is likely due to better recognition of the disorder, earlier treatment, and increasing use of second-line immunotherapy.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
What the sources say
- Supportedcites [11] Irani, 2010, N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes, Brain source
The Results (Relapses; page not provided) report 10 patients with relapses, and the Results (Clinical outcomes; page not provided) identify a cohort of 44—about 23%, within the cited 20–24% range. The citation is attached to the previous-studies relapse rate; the proposed reasons for the lower rate are the citing authors’ interpretation. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [18] Gabilondo, 2011, Analysis of relapses in anti-NMDAR encephalitis, Neurology source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment effects and outcome were assessable in 501 (median follow-up 24 months): 472 (94%) underwent first-line immunotherapy or tumor removal, resulting in improvement within four weeks in 251 (53%).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plainn = 501- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“46/69 (67%) relapses were milder than previous episodes (p<0·0001).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plainn = 45 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Predictors of good outcome were early treatment (OR 0·62, CI 0·50-0·76, p<0·0001)”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plaincorrelationaln = 577 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“lack of ICU admission (OR 0.12, CI 0·06-0·22,p<0·0001)”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of 221 patients who failed first-line therapy, 125 (57%) received second-line immunotherapy resulting in better outcome than those who did not (OR 2·69, CI 1·24-5·80, p=0·012).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plainn = 221 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During the first 24 months, 394/501 reached good outcome (mRS 0-2; median 6 months), and 30 died.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plainn = 30- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 24 month follow-up 204/252 (81%) had good outcome.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment effects and outcome were assessable in 501 (median follow-up 24 months): 472 (94%) underwent first-line immunotherapy or tumor removal, resulting in improvement within four weeks in 251 (53%).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plaindirectn = 472- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“577 patients (1-85 years, median 21) were studied, 212 were children (<18 years).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plainn = 212- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 44
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Experiments where patients’ antibodies were added to cultures of hippocampal neurons or infused into the hippocampus of rodents showed specific antibody-mediated internalization of NMDAR and alteration of the mechanisms of synaptic plasticity.9, 10”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Introduction
What the sources say
- Partly supportedcites [9] Hughes, 2010, Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis, J Neurosci sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [10] Mikasova, 2012, Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis, Brain source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The disorder, named “anti-NMDAR encephalitis”, has since been recognized in patients of all ages, but more frequently in young adults and children with or without teratoma.3, 4”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Introduction
What the sources say
- Supportedcites [3] Dalmau, 2008, Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies, Lancet Neurol source
The Discussion says the disorder largely affects young people, that children can be affected, and that 41% of patients had no clinically detectable tumour. The Results document children both with and without teratoma, while the reported patient age range of 5–76 years supports occurrence across a broad span of ages. (LLM, conf=0.91)
- Supportedcites [4] Florance, 2009, Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents, Ann Neurol source
The Abstract’s Interpretation describes the disorder in adults, frequently young women, and says it also occurs in children and patients without teratoma. The Results report patients as young as 23 months and document teratomas in some, but not all, female patients in both age groups. Together, these passages support the citing sentence’s broad description of age and teratoma status. (LLM, conf=0.86)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients usually present with acute behavioral change, psychosis and catatonia that evolve to include seizures, memory deficit, dyskinesias, speech problems, and autonomic and breathing dysregulation.3”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Introduction
What the sources say
- Partly supportedcites [3] Dalmau, 2008, Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies, Lancet Neurol sourceExperimental — accuracy not yet measured
The Results (page not supplied) report that most patients presented with psychiatric symptoms and later developed seizures, dyskinesias, autonomic instability, and hypoventilation; some also had speech disturbances. The claimed sequence is not fully supported: the paper describes a catatonic-like state developing after decreased consciousness, while some patients had memory loss at presentation. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a center focused in the study of encephalitis of unclear etiology the frequency of anti-NMDAR encephalitis surpassed that of any specific viral etiologies in young individuals.6”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Introduction
What the sources say
- Supportedcites [6] Gable, 2012, The Frequency of autoimmune N-Methyl-D-Aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project, Clin Infect Dis source
The Frequency and Demographics section reports that, among CEP referrals aged 30 or younger with encephalitis of uncertain etiology, 32 had anti-NMDAR encephalitis, compared with 30 with enterovirus and fewer with each other listed viral cause. This supports the claim within the CEP cohort, not as a population-wide frequency estimate. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite the severity of the disease, patients often improve after intensive care support, immunotherapy, and prolonged hospitalizations that require multidisciplinary care.3, 11”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Introduction
What the sources say
- Supportedcites [3] Dalmau, 2008, Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies, Lancet Neurol source
The Discussion reports that, despite severe symptoms requiring multidisciplinary care, 75 of 100 patients recovered or had mild deficits. The Results describe ventilatory support, immunotherapy, and a median hospitalisation of 2.5 months, consistent with the claim's account of intensive support and prolonged care. (LLM, conf=0.90)
- Partly supportedcites [11] Irani, 2010, N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes, Brain sourceExperimental — accuracy not yet measured
The Results (Clinical outcomes and serial estimations of antibodies; page unavailable) document severe disability, an average hospital stay of 160 days, immunotherapy, and improvement associated with earlier treatment. The Discussion (page unavailable) describes prolonged ventilation and intensive-care admissions. The paper does not establish that multidisciplinary care was required or that intensive-care support itself led to improvement. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Epidemiological studies suggest that this disorder is the most common cause of autoimmune encephalitis after acute demyelinating encephalomyelitis (ADEM).5”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Introduction
What the sources say
- Partly supportedcites [5] Granerod, 2010, Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study, Lancet Infect Dis sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that about a fifth of patients had immune-mediated encephalitis, mostly ADEM, and reports 16 antibody-associated cases. The Results (page unavailable) identify NMDA receptor antibodies among the causes, but the passages do not establish that anti-NMDAR encephalitis was more common than the other antibody-associated cause after ADEM. (LLM, conf=0.78)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Follow-up information was obtained at regular intervals (4, 8, 12, 18, and 24 months) after symptom onset; neurological status was assessed with the modified Rankin scale (mRS).12”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Methods > Patients, diagnostic studies, and assessment of treatment and outcome
What the sources say
- Partly supportedcites [12] van Swieten, 1988, Interobserver agreement for the assessment of handicap in stroke patients, Stroke sourceExperimental — accuracy not yet measured
The Subjects and Methods section says the researchers used the modified Rankin scale to assess handicap in stroke patients. It does not report follow-up at 4, 8, 12, 18, and 24 months; its patients were assessed within the first week or within five months after stroke. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, studies suggest that the syndrome and response to treatment may differ between children and adults.4”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Introduction
What the sources say
- Partly supportedcites [4] Florance, 2009, Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents, Ann Neurol sourceExperimental — accuracy not yet measured
The Discussion describes differences between children and adults in symptom frequency and presentation, supporting the syndrome portion. It reports mixed responses to immunotherapy in children and suggests this could relate to their lower rate of tumors, but it does not establish a difference in treatment response between children and adults. Page numbers were not available in our copy. (LLM, conf=0.82)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“If a tumor is found, removal is important because it expedites improvement and decreases relapses.3, 17”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
What the sources say
- Partly supportedcites [3] Dalmau, 2008, Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies, Lancet Neurol sourceExperimental — accuracy not yet measured
The Results report fewer relapses after early tumour treatment (1 of 36 versus 14 of 64) and better outcomes when tumours were removed within four months. Initial improvement occurred sooner in the early-treatment group (median 8 versus 11 weeks), but that difference was not statistically significant (p=0.10). The claim overstates the evidence by saying removal itself expedites improvement and decreases relapses; early treatment usually also included immunotherapy. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [17] Sabin, 2008, Case records of the Massachusetts General Hospital. Case 26-2008. A 26-year-old woman with headache and behavioral changes, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Samples were considered positive if they fulfilled previously reported criteria3 including (1) a characteristic pattern of immunostaining of the neuropil of rat brain, and (2) specific reactivity with HEK293 cells expressing GluN1 (also known as NR1) subunits of the NMDAR.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Methods > Antibody studies
What the sources say
- Partly supportedcites [3] Dalmau, 2008, Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies, Lancet Neurol sourceExperimental — accuracy not yet measured
The Methods (Patients and procedures; page unavailable) say samples were considered positive when three immunohistochemical criteria were met, and describe testing sera and CSF against NR1-expressing HEK293 cells. Our copy does not specify that rat-brain neuropil immunostaining was one of those positivity criteria, so that part of the attributed description remains unsupported. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The discovery of anti-NMDAR encephalitis has changed the diagnostic and treatment approach to several neurologic and psychiatric disorders, and has led to the identification of an expanding group of autoimmune encephalitis related to antibodies against synaptic proteins.19”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
What the sources say
- Partly supportedcites [19] Lancaster, 2012, Neuronal autoantigens—pathogenesis, associated disorders and antibody testing, Nat Rev Neurol sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Rapidly progressive alterations of memory, behavior, cognition, and psychosis previously thought to be idiopathic or viral-induced are now known to be autoimmune.20-23”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
What the sources say
- Not checked — no full text of the sourcecites [20] Chapman, 2011, Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment, Am J Psychiatry source
- Partly supportedcites [21] Kayser, 2011, The emerging link between autoimmune disorders and neuropsychiatric disease, J Neuropsychiatry Clin Neurosci sourceExperimental — accuracy not yet measured
The “Autoimmune Synaptic Encephalitis” section says limbic encephalitides once thought viral or paraneoplastic commonly have an autoimmune cause and can develop over days to weeks with memory and psychiatric symptoms. The claim overgeneralizes this finding: the paper does not say that rapidly progressive changes of these kinds are all now known to be autoimmune, and it describes some cases as idiopathic autoimmune processes rather than formerly thought idiopathic. (LLM, conf=0.84)
- Partly supportedcites [22] Pruss, 2012, IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment, Neurology sourceExperimental — accuracy not yet measured
The Discussion says synaptic autoimmunity can cause acute, severe changes in memory, behavior, and cognition, and the Index patient section describes delusions and hallucinations. But this paper primarily studies slowly progressive impairment; the Clinical course section says none of its seven patients had acute symptoms resembling classic anti-NMDAR encephalitis. Our copy does not establish that these conditions were previously thought to be viral-induced. (LLM, conf=0.88)
- Partly supportedcites [23] Pruss, 2012, NMDA receptor antibodies in herpes simplex encephalitis, Ann Neurol sourceExperimental — accuracy not yet measured
The Abstract’s Interpretation and the Discussion report NMDAR autoantibodies in some patients with herpes simplex encephalitis and suggest that autoimmunity may contribute to their symptoms. They do not establish that the listed memory, behavioral, cognitive, and psychotic symptoms—previously considered idiopathic or viral-induced—are now known to be autoimmune; the Discussion says clinical differences between antibody-positive and antibody-negative patients were not established. Page numbers are unavailable in our copy. (LLM, conf=0.87)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“45 patients had one or multiple relapses (representing a 12% risk within 2 years)”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plainn = 45- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment effects and outcome were assessable in 501 (median follow-up 24 months): 472 (94%) underwent first-line immunotherapy or tumor removal, resulting in improvement within four weeks in 251 (53%).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plainn = 501- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In 177 children, predictors of good outcome and the magnitude of effect of second-line immunotherapy were comparable to those of the entire cohort.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plainn = 177- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During the first 24 months, 394/501 reached good outcome (mRS 0-2; median 6 months), and 30 died.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 501 patients with at least 4 months follow-up, 461 (92%) were treated with first-line immunotherapy, 134 (27%) with second-line immunotherapy (Figure 2 and Table 2), 10 (2%) with tumor removal without immunotherapy, and 29 (6%) were not treated (see below).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Treatments and outcome
plainn = 501- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During the first month of the disease, 498 of 571 (87%) patients developed four or more of the 8 categories of symptoms; only 6 (1%) remained mono-symptomatic (Table 1).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Clinical and diagnostic features
plainn = 571- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of 197 patients with teratoma, 189 (96%) had tumor resection, 20 (11%) of them at neurological relapse or after recovery.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Treatments and outcome
plainn = 197- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MRI of the brain, EEG and CSF studies were abnormal in 180/540 (33%), 432/482 (90%) and 418/532 (79%) patients, respectively.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Clinical and diagnostic features
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The presence of a tumor predominated in patients between 12 and 45 years; only 4 females younger than 12 years (6%), and 7 males (6%, all adults) had a tumor (p<0·0005).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Demographics
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients who received second line immunotherapy, 84/125 reached an mRS 0-2 during the first 24 months, while among those who did not receive second line immunotherapy 49/96 reached an mRS 0-2 (median 10 and 15 months, respectively); at 24 month follow-up 43/55 (78%) and 32/58 (55%) had a good outcome (Figure 3C and 3D).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Analysis of effects of immunotherapy
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Ten studies and one extended review describing at least three patients were identified; five of them included at least twenty-five patients.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Research in context > Systematic review
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Eighty-two of 177 (46%) children failed first-line immunotherapy; in these patients, the magnitude of the effects of second-line immunotherapy (used in 53 cases, 65%; Table S5) was comparable to that of the entire cohort although due to the smaller sample size it did not reach significance (Table S6B, OR 3·35, CI 0·86-12·98, p=0·081).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Treatment and outcome in patients younger than 18 years
plaincorrelationaln = 53- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During the 24 month follow-up, 45 patients (representing a 12% risk) had clinical relapses, which in 15 patients (33%) were multiple (Table S4).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Relapses
plainn = 45- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It confirms the female preponderance, the high frequency of the disease in children, and a higher risk for an underlying teratoma in African-Americans.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Research in context > Interpretation
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“however, “ICU stay” and “time from symptom onset until initiation of treatment” were identified as significant prognostic factors.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Research in context > Interpretation
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Two hundred and seven tumors (94%) were ovarian teratomas, 4 (2%) extraovarian teratomas, and 9 (4%) other tumors (two of each, lung, breast, testicular; one ovarian carcinoma, one thymic carcinomas, and one pancreatic cancer).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Demographics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Two hundred and eleven (37%) of all 577 patients were younger than 18 years, and 28 (5%) were 45 or older.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Demographics
plainn = 577- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During the first 24 months 241/251 reached an mRS 0-2 (median 3 months); at 24 month follow-up 111/115 (97%) of these patients had a good outcome (Figure 3B).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Analysis of effects of immunotherapy
plainn = 251- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In 16 relapses (23%) the severity of symptoms was comparable to that of the initial episode, and in 7 (10%) was worse.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Relapses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The assessment of disease severity showed that 495/571 patients (87%) had a maximum mRS of 5, and 435 (77%) were admitted to the ICU.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Clinical and diagnostic features
plainn = 571- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared with the initial episode, 46/69 (67%) relapses were less severe (as reflected by a lower mRS score measured at the stage of maximum severity), more frequently mono-symptomatic (24, 35%), and resulted in fewer admissions (12, 17%) to the ICU (all p<0·0001).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Relapses
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Two hundred and eleven (37%) of all 577 patients were younger than 18 years, and 28 (5%) were 45 or older.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Demographics
plainn = 577- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Four hundred and sixty-eight patients were female (81%; Figure 1A and Table S1).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Demographics
plainn = 468- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While movement disorders were more frequent in children, memory deficits and central hypoventilation occurred more often in adults (Figure 1C).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Clinical and diagnostic features
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the current study, the frequency of relapses was somewhat less frequent than in previous reports; in addition, the milder nature of the symptoms compared with the initial episodes was noted in most relapses.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Research in context > Interpretation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“First-line immunotherapy was often insufficient to control the disease; in this group of patients the addition of second-line immunotherapy proved to associate significantly with a better outcome compared with those who did not receive second-line immunotherapy.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Research in context > Interpretation
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“at 24 month follow-up 43/55 (78%) and 32/58 (55%) had a good outcome (Figure 3C and 3D).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Analysis of effects of immunotherapy
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Second-line immunotherapy was well tolerated; only 4 patients had serious adverse effects, all reversible (Table 2).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Two hundred and twenty (38%) patients had an underlying neoplasm; of these, 213 were women (representing 46% of all women).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Demographics
plainn = 213- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In univariable analysis, the factors associated with good outcome included, no need for ICU (p<0·0001), early treatment (p=0·009), and low severity of disease within four weeks of onset (maximum mRS, p=0·011).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Treatments and outcome
plaincorrelationaln = 501 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Six of the nine patients with tumors other than teratomas were older than 45 years.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Demographics
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Two hundred and thirty-eight adults (65%) presented with behavioral problems, while 55 children below 12 years (50%) presented with seizures or movement disorders (Figure 1B).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Clinical and diagnostic features
plainn = 238- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The frequency of males was higher in age groups below 12 years (43: 39%) and above 45 (12: 43%, p<0·0001).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Demographics
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder in which the use of immunotherapy and the long-term outcome have not been defined.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Background
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Factors associated with a good outcome (p<0·1) were included in generalized linear mixed models with binary distribution, declaring the subject as random and the other factors as fixed effects.13”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Methods > Statistical analysis
What the sources say
- Not matchedcites [13] Verbeke, 2005
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Indeed, after failing first-line immunotherapy, all these patients remained in a similar poor neurological status, enabling the comparison between those who subsequently received second-line immunotherapy with those who did not.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All mRS scores at defined time points were used (4, 8, 12, 18, and 24 months; e.g. each patient’s follow-up could provide a maximum of 5 scores). The “time point from onset of disease” was included as an additional variable, allowing us to analyze patients with different duration of follow-up.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Methods > Statistical analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our study has the limitations of not being randomized but sets the base for future trials to determine the efficacy of each individual treatment (e.g., steroids, IVIg, plasmapheresis, rituximab, and cyclophosphamide) and duration of immunotherapy.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“After creation of this model, the effect of second-line immunotherapy was determined by adding second-line immunotherapy to the same model applied to only those patients who had failed first-line immunotherapy.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Methods > Statistical analysis
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Symptom presentation varied between children and adults (“more neurological in children”, “more psychiatric in adults”), but in most cases the progression of symptoms evolved towards a similar syndrome.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By establishing the last follow-up assessment at 24 months, our study likely underestimates the frequency and level of recovery because some patients had a shorter follow-up, others continued to improve after 24 months, and those with substantial improvement tended to discontinue follow-ups (Figure S5A and B).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is the first study to provide extensive and structured follow-up and prognostic factors determining outcome.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Research in context > Interpretation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the same reasons, the frequency of mortality is likely overestimated; imputation analysis estimated 7% mortality at 24 months (Figure S5C).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Although selection bias cannot be ruled out in observational studies like this, we could not identify obvious bias between patients who after failing first-line therapies were treated with second-line therapy and those who did not: the severity of symptoms and duration of ICU stay was similar (92% vs 88%, and 88% vs 87%, respectively), and there were no differences in age, gender, ethnicity, and”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our study extends epidemiological and clinical knowledge on anti-NMDAR encephalitis.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Research in context > Interpretation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All patients tested positive for NMDAR antibodies were included in the study without selection criteria other than availability of clinical information.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Methods > Patients, diagnostic studies, and assessment of treatment and outcome
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Factors influencing outcome were assessed by univariable binary logistic regression (good outcome defined as mRS 0-2) independently of the treatments given.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Methods > Statistical analysis
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients with a follow-up shorter than 4 months were excluded from analysis of effects of treatment and outcome.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Methods > Patients, diagnostic studies, and assessment of treatment and outcome
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, second-line immunotherapy with rituximab, cyclophosphamide or both significantly improved the outcome of those who did not respond to first-line therapy, and decreased the frequency of relapses.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This large, observational study demonstrates that immunotherapy and tumor removal if applicable, result in substantial neurological improvement in 81% of patients with anti-NMDAR encephalitis after a median follow-up of 24 months.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Discussion
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The use of immunotherapy and the long-term outcome in anti-NMDAR encephalitis have not been defined.
“Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder in which the use of immunotherapy and the long-term outcome have not been defined.”
The paper relies on this without support.
The efficacy of immunotherapy and its impact in the long-term outcome have not been established.
“However, the efficacy of immunotherapy and its impact in the long-term outcome have not been established.”
The paper relies on this without support.
A substantial number of patients fail to respond to first-line immunotherapy, and for these patients the treatment strategy and outcome are unknown.
“A substantial number of patients fail to respond to first-line immunotherapy, such as steroids, plasmapheresis, and intravenous immunoglobulins (IVIg) and for these patients the treatment strategy and outcome are unknown.”
The authors state this as an assumption.
A systematic analysis of the effects of sequential immunotherapy and their impact on long-term outcome has not been previously done in any of these disorders or other antibody-mediated neurological diseases.
“To our knowledge, a systematic analysis of the effects of sequential (first-, second-line) immunotherapy and their impact on long-term outcome has not been previously done in any of these disorders or other antibody-mediated neurological diseases.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
“577 patients (1-85 years, median 21) were studied, 212 were children (<18 years).”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Demographics
“Two hundred and eleven (37%) of all 577 patients were younger than 18 years”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Abstract > Results
“At 24 month follow-up 204/252 (81%) had good outcome.”
§ Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study > Results > Treatments and outcome
“At 24 month follow-up 203/252 (81%) had a favorable outcome”
Citations
Cites
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Rochester, C. L., & Kradin, R. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432509 · Cited by 3,875
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492
Self-citationModels for Discrete Longitudinal Data
Molenberghs, G., & Verbeke, G. (2005) · Springer eBooks · doi:10.1007/0-387-28980-1 · Cited by 1,487
Granerod, J., Ambrose, H. E., Davies, N. W., Clewley, J. P., Walsh, A. L., Morgan, D., Cunningham, R., Zuckerman, M., Mutton, K. J., Solomon, T., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70222-x · Cited by 1,358
Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis
Hughes, E. G., Peng, X., Gleichman, A. J., Lai, M., Zhou, L., Tsou, R., Parsons, T. D., Lynch, D. R., Dalmau, J., & Balice-Gordon, R. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0167-10.2010 · Cited by 1,143
Self-citationAnti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents
Florance, N. R., Davis, R. L., Lam, C., Szperka, C., Zhou, L., Ahmad, S., Campen, C. J., Moss, H., Peter, N., Gleichman, A. J., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21756 · Cited by 1,090
Self-citation
Cited by
Sorted by citations
Items 2,701–2,800 of 3,166
Kacar, E., Seiser, A., Seifert‐Held, T., & Struhal, W. (2021) · psychopraxis neuropraxis · doi:10.1007/s00739-021-00695-3
Seizures and Antibodies Against Surface Antigens
Dalmau, J. O., & Graus, F. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108696722.010
Self-citationAbnormal Movements in Neurological Autoimmune Disorders
Dalmau, J. O., & Graus, F. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108696722.022
Self-citationDalmau, J. O., & Graus, F. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108696722.023
Self-citationImmunomodulatory Therapy in Treatment of Drug-Resistant Epilepsy (Literature Review)
Зайцев, И. И., & Sa, L. (2022) · Неврология и нейрохирургия Восточная Европа · doi:10.34883/pi.2021.11.4.052
Seventeen-Year-Old Female With History of Depression Presented With Mania and Enuresis
Tunc, E. M., Otten, C. E., Kodish, I. M., Kim, S., Kochar, A., Novotny, E. J., & Yoshida, H. (2022) · PEDIATRICS · doi:10.1542/peds.2021-051176
Dalmau, J. O., & Graus, F. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108696722.007
Self-citationDorris, L., Thomson, A., Adey, C., & Hind, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00052-9
Chorea, Ballism, and Athetosis
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00014-7
Stimulation Treatment for Medication-Resistant Epilepsy
Stern, J. M., Sankar, R., & Sperling, M. R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316492376.020
Kramer, A. H., & Bleck, T. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-19668-8_19
Storch-Hagenlocher, B., Wildemann, B., Berlit, P., & Krämer, M. (2015) · Springer eBooks · doi:10.1007/978-3-662-46500-4_33
Encefalitis anti-NMDAR. ¿Cómo y cuándo sospecharla?
Smiliansky, N., Iraola, M. V., Díaz-Cuña, C., & Bruno, G. (2021) · Revista Española de Casos Clínicos en Medicina Interna · doi:10.32818/reccmi.a6n1a5
Kazlauskaitė, J., Giedraitienė, N., Masaitienė, R., & Klimašauskienė, A. (2021) · Neurologijos seminarai · doi:10.29014/ns.2021.24
Anti-N-methyl-D-aspartate receptor encephalitis in a 17-year-old girl – a case report
Witczak, C., Kemnitz, P., Pieczonka-Ruszkowska, I., Mania, A., Mazur‐Melewska, K., & Figlerowicz, M. (2021) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2021.0055
Anti-N-Methyl-D-Aspartate Receptor Encephalitis (ANMDARE) in a Patient With Hashimoto’s Thyroiditis
Jain, A., Thomas, J., & Chong, H. (2022) · Cureus · doi:10.7759/cureus.23109
Harrar, D. B., Mondok, L. J., Adams, S., & Farias‐Moeller, R. (2022) · Critical Care Clinics · doi:10.1016/j.ccc.2021.11.006
Heo, S. T. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0029
When Agitation, Hallucination, and Paranoia Mean More Than Psychosis
Santi, A. D., Emamian, A., Appu, M., Tcheng, W. Y., & Fernández, K. S. (2022) · Pediatrics in Review · doi:10.1542/pir.2020-004887
Rheumatoid arthritis in a patient with anti-N-methyl-D-aspartate receptor encephalitis
Zhuo, N., Wang, G., Li, J., & Wen, Z. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-01947-8
彭, 慧. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124393
Shosha, E., & Pittock, S. J. (2019) · doi:10.1093/med/9780190862923.003.0104
Wang, Y., Miao, A., Shi, Y., Ge, J., Wang, L., Xu, H., Yu, C., Yu, Y., Huang, S., Jiang, W., et al. (2019) · doi:10.21203/rs.2.17708/v1
Zheng, Y., Zhao, P., Lian, Y., Li, L., Chen, Y., Wang, C., & Zhang, Q. (2019) · Research Square · doi:10.21203/rs.2.9845/v1
Venkatesan, A., & Probasco, J. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-92678-0_12
Stern, J. M., Sankar, R., & Sperling, M. R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316492376.024
Autoantikörper gegen Glutamat-Rezeptoren Typ NMDA
STÖCKER, W. (2017) · Springer eBooks · doi:10.1007/978-3-662-49054-9_383-1
Characteristics of cerebrospinal fluid cytology in anti-N-methyl-D-aspartate receptor encephalitisPreprint
Liu, H., Ren, H., Zhao, Y., Fan, S., Gao, X., Shi, Y., Zhao, J., Li, W., Zhang, J., & Guan, H. (2019) · Research Square · doi:10.21203/rs.2.14478/v1
Response to “Management of Anti– N -Methyl- d -Aspartate (NMDA) Receptor Encephalitis in Children”
Brenton, J. N. (2017) · Journal of Child Neurology · doi:10.1177/0883073817689648
Jacob, S., & Vincent, A. C. (2019) · Springer eBooks · doi:10.1007/978-981-13-7381-7_2
Autoantikörper gegen Glutamat-Rezeptoren Typ NMDA
STÖCKER, W. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_383
Vaišvilas, M., Mameniškienė, R., & Barkauskienė, A. (2020) · Neurologijos seminarai · doi:10.29014/10.29014/ns.2020.08
Greenwood, R. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727344630.793555826
Muñoz, D., Hernández, D. L., & Giraldo, N. D. (2017) · Colombian Journal of Anesthesiology · doi:10.1097/01819236-201712001-00014
Blaes, F. (2017) · Springer eBooks · doi:10.1007/978-3-662-44768-0_103-1
Prüß, H. (2015) · NeuroTransmitter · doi:10.1007/s15016-015-0506-6
van Sonderen, A., & Titulaer, M. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-01225-4_16
Self-citationAutoimmune Encephalitis Affecting Synaptic Proteins☆
Rosenfeld, M. R., & Dalmau, J. O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.04376-5
Self-citationAnti-NMDA Receptor Encephalitis and Other Autoimmune and Paraneoplastic Movement Disorders
Panzer, J. A., Dalmau, J. O., & Dale, R. C. (2021) · Current clinical neurology · doi:10.1007/978-3-030-75898-1_16
Self-citationSindromi neurologiche paraneoplastiche
Alberto, T., Honnorat, J., & Joubert, B. (2022) · EMC - Neurologia · doi:10.1016/s1634-7072(22)46429-4
Llerena-Rengel, P. A., Barragán, F. E. R., & Vélez-Páez, J. L. (2022) · Bionatura · doi:10.21931/rb/2022.07.02.34
Aryal, R., Shrestha, S., Homagain, S., Tiwari, S. B., & Ojha, R. (2022) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12713
Askandaryan, A. S., Naqvi, A., Varughese, A., & Rimawi, D. (2022) · Cureus · doi:10.7759/cureus.25751
Autoimmunity to glutamate receptor channels
Kawachi, I. (2022) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12650
Self-citationChen, X., Fang, L., Wang, Y., Dai, Z., Wang, J., Shu, Y., & Qiu, W. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4092676
Anti N-methyl-D-aspartate receptor encephalitis: A case series from Myanmar
Nyein, A. M., Win, K. Z., Naing, M. T., Kyinn, S., & Sann, A. A. (2022) · Neurology Asia · doi:10.54029/2022swp
Anti-NMDA Receptor Encephalopathy Secondary to an Ovarian Teratoma
Krupadev, V., Johnson, S., Arogundade, E. O., & Jones, C. (2022) · American Journal of Hospital Medicine · doi:10.24150/ajhm/2022.002
Toreja, A. L. D., & Magno, A. D. L. (2022) · Philippine Journal of Obstetrics and Gynecology · doi:10.4103/pjog.pjog_19_22
Is it psychosis, or an autoimmune encephalitis?
Baum, M. L. (2022) · Current Psychiatry · doi:10.12788/cp.0273
VII. Diagnosis and Treatment of Autoimmune Encephalitis
Kimura, A. (2021) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.110.1601
Huang, H., Ye, L., Li, S., Luo, X., & Wu, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1509233/v1
Autoimmune and Paraneoplastic Encephalopathies
Rini, J. F., Peet, B. T., & Geschwind, M. D. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197574317.003.0021
Kornbluh, A. B., McLendon, L. A., & Banwell, B. (2022) · Neuroimmunology Reports · doi:10.1016/j.nerep.2022.100147
Toàn, P. V., & Khôi, V. H. (2022) · Tạp chí Y học Việt Nam · doi:10.51298/vmj.v518i2.3414
19/w mit Wesensänderung und therapierefraktärem Status epilepticus
Prüß, H., Rößling, R., Musleh, R., & Günther, A. (2022) · DGNeurologie · doi:10.1007/s42451-022-00483-2
Ali, O., Elhadd, K. T., Forcadela, M., Rocchi, C., Lyons-Nandra, S., Hamid, S. H. M., Kneen, R., Burness, C. E., & Huda, S. (2022) · Neuroimmunology Reports · doi:10.1016/j.nerep.2022.100149
Stamm, B. J., DiBiase, R., Harris, G. R., Kaprielian, H., Brahmbhatt, N., Wu, A. D., Baker, J. J., & Liotta, E. M. (2022) · Neurology · doi:10.1212/wnl.0000000000201500
Haddad, A., Rambaud, T., Ba, S. T., Manceau, P., Degos, B., & Mongin, M. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.08.001
Falcicchio, G., Boero, G., Francavilla, T., Alicino, A., Sgobio, R., Trojano, M., & Neve, A. L. (2022) · Epilepsy & Behavior Reports · doi:10.1016/j.ebr.2022.100576
Anti-NMDA Receptor Encephalitis in a 12-Year-Old Girl
Boyer, A. G., & Christensen, S. (2022) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2022.180202
ANTI-NMDA-R encephalitis: case report
Tosunoğlu, B., Güneş, H. N., Kına, H. M., & Çokal, B. G. (2022) · Postępy Psychiatrii i Neurologii · doi:10.5114/ppn.2022.120492
A case report of adolescent anti-NMDAR encephalitis with depressive symptoms (eng)
Fındık, O. T. P., Öztürk, G., Akbeyaz, İ. H., Özcan, S. A., Unver, O. I., Türkdoğan, D., & Fiş, N. P. (2022) · Journal of Clinical Psychiatry · doi:10.5505/kpd.2022.83436
Child with Suspected Autoimmune Encephalitis
Joseph, J., & Brenton, J. N. (2022) · Springer eBooks · doi:10.1007/978-3-031-10494-7_32
Anthony, D., & Marshall, W. (2022) · Journal of Family Medicine and Disease Prevention · doi:10.23937/2469-5793/1510152
Anti-NMDA Receptor Encephalitis in Children: Report of Four Cases from Bahrain
Mohamed, A. K. E. A., & Ali, A. K. E. (2022) · Journal of the Bahrain Medical Society · doi:10.26715/jbms.34_4_5
Clinical characteristics of anti-NMDAR encephalitis in adult Southeast Asian males
Tan, Y., Ong, C. S., Siow, I., & Yong, K. P. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2021-007
Actualités dans le diagnostic et le traitement des encéphalites auto-immunes
Lamblin, F., Joubert, B., & Honnorat, J. (2023) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2023.01.008
Delta brush on EEG: a characteristic EEG finding in autoimmune encephalitis
Saleem, S., Siddiqui, S. J., Qureshi, F. A., & Kanwar, D. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-249899
Encefalite autoimune antirreceptor NMDA na infância e causas virais: uma revisão bibliográfica
Razera, C., & Ferreira, R. D. M. (2023) · Research Society and Development · doi:10.33448/rsd-v12i2.40267
Autoimmune encephalitis: Should we consider third‐line immunotherapies earlier?
Kelly, M. J., & Irani, S. R. (2023) · European Journal of Neurology · doi:10.1111/ene.15728
Anti-N-methyl-D-Aspartate Receptor Encephalitis
Malhotra, D., Sane, S., Mane, S., & Hajirnis, O. (2023) · Indian Pediatrics Case Reports · doi:10.4103/ipcares.ipcares_187_22
Experience with anti NMDA receptor antibody encephalitis in a tertiary care hospital in Pakistan
Rajput, H. M., Waqar, Z., Hassan, M., Khattak, N. N., Hassan, U., Athar, I., & Badshah, M. (2023) · Pakistan Journal of Neurological Sciences · doi:10.56310/pjns.v17i03.189
Síndromes paraneoplásicos del sistema nervioso
Pascual, F. H., & Izquierdo, A. Y. (2023) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2023.02.022
Marsters, C. M., Iskhakova, S., Powe, L., & Budhram, A. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.220938
Autoimmun-Enzephalitis bei einer 14 Jahre alten Patientin
Faßhauer, M. (2023) · Arthritis und Rheuma · doi:10.1055/a-2006-9574
Phượng, V. T. M., An, P. N., & Thuỷ, P. T. B. (2023) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v162i1.1317
Wénin, J., Bronchain, M., Sellimi, A., & Pesch, V. V. (2023) · Acta Neurologica Belgica · doi:10.1007/s13760-023-02241-x
Srijithesh, P., Shivaram, S., Gupta, M., Taallapalli, A. V. R., Nashi, S., & Mahadevan, A. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_793_22
Encefalitis autoinmune posherpética. Caso clínico pediátrico
(2023) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2022-02941
Plasma lipid profiles and homocysteine levels in anti-N-methyl-D-aspartate receptor encephalitis
Wang, Z., Qiao, S., Wang, L., Wang, K., Zhang, R., Jin, Y., Wu, H.-K., & Liu, X. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1148450
Chronisch entzündliche ZNS-Erkrankungen
Bigi, S., & Chan, A. (2023) · Springer eBooks · doi:10.1007/978-3-662-65724-9_15
Research Progress in Epileptic Seizures Associated with Autoimmune Encephalitis
崔, 绿. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1351111
Hasan, S. F., Lutfi, L., Shukur, M., Alemam, S., Esmaeel, H., & Nawaz, F. A. (2023) · Cureus · doi:10.7759/cureus.39960
Premier épisode psychotique causé par une encéphalite à anticorps anti–récepteurN-méthyl-d-aspartate
Marsters, C. M., Iskhakova, S., Powe, L., & Budhram, A. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.220938-f
Zhang, M., Wang, J., Sun, D., Wang, J., Zhang, J., & Xu, J. (2023) · Research Square · doi:10.21203/rs.3.rs-3081126/v1
Naka, M., Inaba, A., Miyasaka, H., Suzue, K., Ishigaki, J., Shibuya, H., Hara, K., Ohishi, N., Sugiyama, Y., Shiio, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3053345/v1
Garg, S., & Chauhan, A. (2021) · Journal of the Scientific Society · doi:10.4103/jss.jss_107_20
Paraneoplastic Neurological Syndromes
Valencia-Sánchez, C., & Mrugała, M. M. (2023) · doi:10.1093/med/9780197573778.003.0024
Autoimmune anti-NMDA receptor encephalitis on the background of COVID-19: a clinical case
Ulyanova, O. V., Ермоленко, Н. А., Анатольевна, Д. А., Викторовна, Б. В., Ивановна, Д. Т., Kulikov, A. V., Golovina, N. P., Kuleshova, E. O., & Kuslivaya, A. V. (2023) · Journal of clinical practice · doi:10.17816/clinpract225851
Anti-NMDA Receptor Encephalitis: A Rare but Important Auto-Immune Cause of Encephalitis
Ghoauri, M. S. A., Butt, N. I., Javed, M. U., Rasheed, M. B., Luqman, S., & Ali, S. (2022) · National Journal of Health Sciences · doi:10.21089/njhs.73.0136
Dysimmune Encephalitis: Clinical Study
Hakim, S. A., & Smail, D. (2023) · Journal of Neuroscience and Neurological Research · doi:10.59657/2837-4843.brs.23.008
Entzündliche und erregerbedingte Erkrankungen
Warnke, C. (2023) · Springer eBooks · doi:10.1007/978-3-662-64112-5_11
Autoimmune Encephalitis: A Literature Review
Stoshevska, T. D., Nikoloska, S., Stoshevski, B., Nikoloski, M., Veljanovski, D., & Dejanova-Panov, S. (2023) · South East European Journal of Immunology · doi:10.3889/seejim.2023.6032
Li, S., Hu, X., Yang, Y., Wang, J., Hong, Z., Zhou, D., & Li, J. (2023) · medRxiv · doi:10.1101/2023.07.27.23292878 · Cited by 1
Friedman, G., Hammock, J., Holtzman-Hayes, N., & Gluck, L. (2023) · The Neurohospitalist · doi:10.1177/19418744231196388
Autoimmune processes in neurological patients are much more common than presently suspected
Goertzen, A., Altawashi, A. K., Rieck, J., & Veh, R. W. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11901-0
Rehabilitation of Patients with Encephalitis with Memory Disturbance
Urakami, Y. (2023) · リハビリテーション医学 : 日本リハビリテーション医学会誌 · doi:10.2490/jjrmc.60.491
Funayama, M. (2023) · リハビリテーション医学 : 日本リハビリテーション医学会誌 · doi:10.2490/jjrmc.60.498
History of schizophrenia : From schizophrenia to autoimmune psychosis
Takaki, M. (2023) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.135.63
Immunvermittelte Enzephalitiden
Longoni, G., & Yeh, E. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-28842-5_2
Metadata
- Authors
- Titulaer, M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L. S., Benseler, S. M., Kawachi, I., Martinez-Hernandez, E., Aguilar, E., Gresa-Arribas, N., Ryan-Florance, N., Torrents, A., Saiz, A., Rosenfeld, M. R., Balice-Gordon, R., Graus, F., & Dalmau, J.
- Affiliations
- Hospital of the University of Pennsylvania (US)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- California Department of Public Health (US)
- Kitasato University Hospital (JP)
- Columbia University (US)
- University of Toronto (CA)
- Brain Research Institute, Niigata University (JP)
- Hospital Clínic de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Dalmau, Josep
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 12
- Issue
- 2
- Pages
- 157-165
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC3563251
- OpenAlex
- W2163022996
- Semantic Scholar
- 620c73775fc208276d59ab7e761fc4b6da598ff4
- Cited by
- 3,165
- References
- 28
- Citations by year
- 2026: 225 · 2025: 231 · 2024: 249 · 2023: 239 · 2022: 287 · 2021: 329 · 2020: 296 · 2019: 274 · 2018: 222 · 2017: 193 · 2016: 202 · 2015: 169 · 2014: 152 · 2013: 90
- FWCI
- 129.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Japan Society for the Promotion of Science (23591236)
- National Institute on Aging (P50AG008702)
- National Institute of Mental Health (R01MH094741)
- National Cancer Institute (R01CA089054, R56CA089054, R01CA107192)
- National Institute of Neurological Disorders and Stroke (RC1NS068204, R01NS077851)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
- Keywords
- anti-NMDA receptor encephalitis, NMDA receptor antibodies, immunotherapy, rituximab, cyclophosphamide, plasmapheresis, intravenous immunoglobulin, corticosteroids, tumor resection, long-term outcomes, prognostic factors, modified Rankin Scale, autoimmune encephalitis, children, adults
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Analysis of Variance, Autoantibodies, Child, Child, Preschool, Female, Humans, Immunotherapy, Infant, Male, Middle Aged, Retrospective Studies, Time Factors, Cohort Studies, Logistic Models, Receptors, N-Methyl-D-Aspartate, Immunoglobulins, Intravenous, Treatment Outcome, Observation, Young Adult, Anti-N-Methyl-D-Aspartate Receptor Encephalitis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-03, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-03 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
